The results showed that these nanocarriers performed their cancer‐fighting functions mostly through the combinatorial anticancer effects of gemcitabine and erlotinib, which were augmented via pancreatic cancer fibrotic stroma modulation—attributed to NF‐ĸB‐mediated IL‐1β production hindrance via IRAK4 suppressive activity (Figure 20c).148. This evidence concerns the gene IRAK4 and pancreatic neoplasm.